The Armchair Analyst

Level up your ASX biotech knowledge

Recent Articles

The $2m Oversight: Don't forget to Exercise

The $2m Oversight: Don't forget to Exercise

Jan 23, 2026

•

5 min read

Big Volume, Boring News: Why Stocks Move on “Nothing”

Big Volume, Boring News: Why Stocks Move on “Nothing”

Jan 22, 2026

•

9 min read

Explained: Why Options Magnify Risk and Reward

Explained: Why Options Magnify Risk and Reward

Jan 21, 2026

•

12 min read

Whale Watching: What is driving the share price?

Whale Watching: What is driving the share price?

Jan 20, 2026

•

10 min read

On Edge: The Moment That Makes, or Breaks, a Biotech

On Edge: The Moment That Makes, or Breaks, a Biotech

Jan 19, 2026

•

13 min read

The Cannabis Merger Trade: Liquidity First, Value Later

The Cannabis Merger Trade: Liquidity First, Value Later

Jan 16, 2026

•

11 min read

The moment that Chinese biotechs went from 'too hard' to 'too hard to ignore'

The moment that Chinese biotechs went from 'too hard' to 'too hard to ignore'

Jan 15, 2026

•

11 min read

The Art of the Capital Raise

The Art of the Capital Raise

Jan 14, 2026

•

7 min read

The Problem With Being the Best Stock in the Market

The Problem With Being the Best Stock in the Market

Jan 13, 2026

•

9 min read

What happens when pharma’s biggest accidental blockbuster comes off patent?

What happens when pharma’s biggest accidental blockbuster comes off patent?

Jan 12, 2026

•

9 min read

Biotech’s biggest week starts as the M&A window opens

Biotech’s biggest week starts as the M&A window opens

Jan 9, 2026

•

7 min read

The $12M Prize: How PER Survived Two Board Coups and Lived to Fight On

The $12M Prize: How PER Survived Two Board Coups and Lived to Fight On

Jan 8, 2026

•

8 min read